Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
hemophilia-a-treatment-market

Hemophilia A Treatment Market [By Standard of Diagnosis (Mild Moderate & Severe), By Approved Drugs (Afstyla, Eloctate, Hemlibra, Kogenate FS, Kovaltry, Nuwiq & Obizur), By Care Delivery Model (Prophylaxis, On-demand therapy & Inhibitor therapy) and By Regions]: Market Estimate & Forecast, 2016 - 2022

Published: Feb 2018
Pages: 100
Format: PDF
Report ID: PM1107
License and Pricing
Buy Now Inquire Before Buying

Report Summary

The global Hemophilia A treatment market was valued at approximately USD 8 billion in 2016. The Report covers the Hemophilia A therapeutic area, prevalent population, current treatment and diagnosis patterns. The Report provides the forecast of Hemophilia A treatment market globally, by G7 countries, disease care at product level. The Report also offers an in-depth view of the Hemophilia A treatment market opportunities by focusing on major drivers facing this market. Hemophilia A, also called factor VIII (FVIII) deficiency or classic Hemophilia, is a genetic disorder caused by missing or defective factor VIII, a clotting protein. Although it is passed down from parents to children, about 1/3 of cases are caused by a spontaneous mutation, a change in a gene.

Hemophilia A market accounts for the largest share in total Hemophilia treatment market due to the rising prevalence and increase in demand of prophylactic treatments. In terms of the geographic distribution, Unites States holds the dominant market position followed by top five European countries (France, Germany, Italy, Spain and the U.K.) and Japan. The major drivers of the U.S. market are rising prevalent cases of Hemophilia A, awareness of the disease, access to new treatment modalities, improved diagnosis, and increase in the usage of both prophylactic and recombinant treatment options.

North America Hemophilia A Treatment Market By Care Delivery Model, 2016 - 2022

North America Hemophilia A Treatment Market By Care Delivery Model, 2016 - 2022

Inside circle shows data for 2016 and outer circle shows data for 2022

The market for Haemophilia A treatment market looks commercially significant driven by increase rising demand for recombinant and prophylaxis products and continual increase in new cases diagnosed each year worldwide. Despite the existence of available effective treatment options in Hemophilia A, there is currently no cure for Hemophilia A. Also, these therapies are expensive and involve lifelong therapy to prevent bleeding.

Segment Analysis

Polaris Market Research has provided the forecasts of the Global Hemophilia A treatment Market from 2016-2022. The major segments which has been investigated in the global market from 2016-2022 are:

  • Market Analysis by Hemophilia A
  • Market Analysis by Treatment Class/Marketed Drugs
  • Market Analysis by G7 countries

SAMPLE TABLE
North America Hemophilia A Treatment Market, By Care Delivery Model, 2016 - 2022 
(USD Million)

North America Hemophilia A Treatment Market, By Care Delivery Model, 2016 - 2022 (USD Million)

Key questions answered by the report

  • What is the current market size and forecasts of Hemophilia A Treatment
  • What is the market opportunity for Hemophilia A Treatment therapies
  • What is the market opportunity for Hemophilia A Treatment
  • What is the market opportunity for Hemophilia A Treatment by delivery model
  • What is the market opportunity for Hemophilia A Treatment by end user
  • How much is the estimated market for Hemophilia A Treatment in North America and Asia Pacific during the forecast period.
  • What are the companies in this market and how are they classified.
  • What are the available opportunities and who are the top market players in this
  • What are the major drivers and challenges of global Hemophilia A Treatment market
  • Which are the major approved drugs segments and what traction are they gaining in the market.

 

Table of Contents

  1. Hemophilia A Treatment Market Summary
  2. Hemophilia A Treatment Overview
    1. Disease Definition
    2. Hemophilia Types
      1. Mild
      2. Moderate
      3. Severe
    3. Disease Symptoms
  3. Current Diagnosis Patterns
  4. Treatment Patterns of Hemophilia A
    1. Treatment Guidelines for Hemophilia A
  5. Hemophilia A treatment Epidemiology -Prevalent Population & Segmentations
    1. Prevalent Population Globally (2016-2022)
      1. Mild Prevalent Cases (2016-2022)
      2. Moderate Prevalent Cases (2016-2022)
      3. Severe Prevalent Cases (2016-2022)
    2. Prevalent Population in the United States (2016-2022)
      1. Mild Prevalent Cases (2016-2022)
      2. Moderate Prevalent Cases (2016-2022)
      3. Severe Prevalent Cases (2016-2022)
    3. Prevalent Population in Germany (2016-2022)
      1. Mild Prevalent Cases (2016-2022)
      2. Moderate Prevalent Cases (2016-2022)
      3. Severe Prevalent Cases (2016-2022)
    4. Prevalent Population in France (2016-2022)
      1. Mild Prevalent Cases (2016-2022)
      2. Moderate Prevalent Cases (2016-2022)
      3. Severe Prevalent Cases (2016-2022)
    5. Prevalent Population in Italy (2016-2022)
      1. Mild Prevalent Cases (2016-2022)
      2. Moderate Prevalent Cases (2016-2022)
      3. Severe Prevalent Cases (2016-2022)
    6. Prevalent Population in Spain (2016-2022)
      1. Mild Prevalent Cases (2016-2022)
      2. Moderate Prevalent Cases (2016-2022)
      3. Severe Prevalent Cases (2016-2022)
    7. Prevalent Population in United Kingdom (2016-2022)
      1. Mild Prevalent Cases (2016-2022)
      2. Moderate Prevalent Cases (2016-2022)
      3. Severe Prevalent Cases (2016-2022)
    8. Prevalent Population in Japan (2016-2022)
      1. Mild Prevalent Cases (2016-2022)
      2. Moderate Prevalent Cases (2016-2022)
      3. Severe Prevalent Cases (2016-2022)
  6. Current and Future Approaches of Care in Hemophilia A Treatment
    1. Pre-replacement Therapy
    2. Replacement Therapy
      1. On Demand
      2. Prophylaxis
    3. Non-Replacement Therapy
      1. Mimetics/Agonists
    4. Gene Therapy
  7. Marketed Drugs & Sales Forecast in Hemophilia A Treatment
    1. CSL Behring: Afstyla (Antihemophilic Factor (Recombinant), Single Chain)
      1. Product Profile
      2. Safety & Efficacy
      3. Afstyla Sales Forecast-2016-2022
    2. Biogen IDEC: Eloctate [Antihemophilic Factor (Recombinant), Fc Fusion Protein]
      1. Product Profile
      2. Safety & Efficacy
      3. Eloctate Sales Forecast-2016-2022
    3. Genentech: Hemlibra (emicizumab-kxwh)
      1. Product Profile
      2. Safety & Efficacy
      3. Hemlibra Sales Forecast-2016-2022
    4. Bayer: Kogenate FS (Antihemophilic Factor Recombinant)
      1. Product Profile
      2. Safety & Efficacy
      3. Kogenate FS Sales Forecast-2016-2022
    5. Bayer: Kovaltry [Antihemophilic Factor (Recombinant)
      1. Product Profile
      2. Safety & Efficacy
      3. Kovaltry Sales Forecast-2016-2022
    6. Octapharma: Nuwiq (recombinant Factor VIII)
      1. Product Profile
      2. Safety & Efficacy
      3. Nuwiq Sales Forecast-2016-2022
    7. Shire (Baxter): Obizur [Antihemophilic Factor (Recombinant), Porcine Sequence]
      1. Product Profile
      2. Safety & Efficacy
      3. Obizur Sales Forecast-2016-2022
  8. Market Size & Forecast of Hemophilia A Treatment(2016-2022)
    1. Market Forecast by Disease Care
      1. Prophylaxis-Market Forecast (2016-2022)
      2. On-demand therapy-Market Forecast (2016-2022)
      3. Inhibitor therapy- Market Forecast (2016-2022)
    2. Market Forecast by G7 Countries (2016-2022)
      1. United States- Market Forecast (2016-2022)
      2. Germany- Market Forecast (2016-2022)
      3. France-Market Forecast (2016-2022)
      4. Italy- Market Forecast (2016-2022)
      5. Spain- Market Forecast (2016-2022)
      6. United Kingdom- Market Forecast (2016-2022)
      7. Japan- Market Forecast (2016-2022)
  9. Factors Driving the Market of Hemophilia A Treatment
  10. Factors Restraining the Market of Hemophilia A Treatment
  11. About Polaris Market Research
  12. Disclaimer
  13. Sales Support


Report Content

The Marketed Therapies covered in the forecast from 2016-2022 are:

  • Afstyla Sales Forecast-2016-2022
  • Eloctate Sales Forecast-2016-2022
  • Hemlibra Sales Forecast-2016-2022
  • Kogenate FS Sales Forecast-2016-2022
  • Kovaltry Sales Forecast-2016-2022
  • Nuwiq Sales Forecast-2016-2022
  • Obizur Sales Forecast-2016-2022

The Major Indications in Hemophilia A Treatment Therapy area:

  • Prophylaxis-Market Forecast 2016-2022
  • On-demand therapy-Market Forecast 2016-2022
  • Inhibitor therapy- Market Forecast 2016-2022

The Forecast of Hemophilia A Treatment Market by G7 Countries (2016-2022)

  • United States- Market Forecast (2016-2022)
  • Germany- Market Forecast (2016-2022)
  • France-Market Forecast (2016-2022)
  • Italy- Market Forecast (2016-2022)
  • Spain- Market Forecast (2016-2022)
  • United Kingdom- Market Forecast (2016-2022)
  • Japan- Market Forecast (2016-2022)

 Leading Companies investigated in the Report are

  • CSL Behring
  • Shire
  • Bayer
  • Biogen
  • Genentech
  • Bioverativ
  • Alnylam Pharmaceuticals
  • Sanofi (Genzyme)
  • BioMarin Pharmaceutical
  • Hoffmann-La Roche
  • Sinocelltech Ltd.
  • Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
  • Octapharma
  • LFB USA, Inc.
  • Novo Nordisk A/S
  • Pfizer

 

 

Request For customization

 

By using this form you agree with the storage and handling of your data by this website.

Speak to Analyst

 

By using this form you agree with the storage and handling of your data by this website.

Inquire Before Buying

 

By using this form you agree with the storage and handling of your data by this website.

Request for Sample

By using this form you agree with the storage and handling of your data by this website.